| [1] |
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822): 1245-55.
|
| [2] |
Wang L, Zhang Y, Li H, et al. Hint1 inhibits growth and activator protein-1 activity in human colon cancer cells[J]. Cancer Res, 20 07, 67(10): 4700-8.
|
| [3] |
Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinomaassociated t(3;8) breakpoint, is abnormal in digestive tract cancers[J]. Cell, 1996, 84(4): 587-97.
|
| [4] |
Al-Temaimi RA, Jacob S, Al-Ali W, et al. Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer[J]. J Histochem Cytochem, 2013, 61(9): 627-38.
|
| [5] |
Chen P, Li J, Wang Y, et al. Detection of FHIT and p16 mRNA deletion in biopsy specimens obtained by bronchoscopy for the diagnosis of lung cancer[J]. Int J Biol Markers, 2013, 28(3): 25 9-66.
|
| [6] |
Yu YC, Sun FY, Li Z, et al. Relationship between aberrant FHIT transcripts and hepatocellular carcinoma[J]. Zhonghua Gan Bing Za Zhi, 2003, 11(9): 39-40. [于永春, 孙奋勇, 李智, 等. 脆性组氨 酸三联体基因异常转录与肝癌关系的研究[J]. 中华肝脏病杂 志, 2003, 11(9): 39-40.]
|
| [7] |
Nam CW, Shin JW, Park NH. Fragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea[J]. World J Gastroenterol, 2008, 14 (22): 3526-33.
|
| [8] |
Gramantieri L, Chieco P, Di Tomaso M, et al. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis[J]. Clin Cancer Res, 1999, 5(11): 34 68-75.
|
| [9] |
Zekri AR, Bahnassy AA, Hafez M, et al. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2005, 20(1): 87-94.
|
| [10] |
Kannangai R, Sahin F, Adegbola O, et al. FHIT mRNA and protein expression in hepatocellular carcinoma[J]. Mod Pathol, 20 04, 17(6): 653-9.
|
| [11] |
Schlott T, Ahrens K, Ruschenburg I, et al. Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia[J]. Br J Cancer, 1999, 80 (1-2): 73-8.
|
| [12] |
Chen YJ, Chen PH, Chang JG. Aberrant FHIT transcripts in hepatocellular carcinomas[J]. Br J Cancer, 1998, 77(3): 417-20.
|
| [13] |
Huang Q, Liu Z, Xie F, et al. Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocar cinoma cells by blocking PI3K-Akt pathway[J]. Scientific World J, 20 14, 2014: 179698.
|
| [14] |
Kelley K, Berberich SJ. FHIT gene expression is repressed by mitogenic signaling through the PI3K/AKT/FOXO pathway[J]. Am J Cancer Res, 2011, 1(1): 62-70.
|
| [15] |
Saldivar JC, Miuma S, Bene J, et al. Initiation of genome instability and preneoplastic processes through loss of Fhit expression[J]. PLoS Genet, 2012, 8(11): e1003077.
|
| [16] |
Palumbo E, Tosoni E, Matricardi L, et al. Genetic instability of the tumor suppressor gene FHIT in normal human cells[J]. Genes Chromosomes Cancer, 2013, 52(9): 832-44.
|
| [17] |
Ke Y, Zhong JH, You XM, et al. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy[J]. Zhongguo Zhong Liu Lin Chuang, 2013, 40(19): 11 84-8. [柯阳, 钟鉴宏, 游雪梅, 等. 抗病毒治疗对乙型肝炎病 毒相关性肝细胞癌患者根治性术后的影响[J]. 中国肿瘤临床, 20 13, 40(19): 1184-8.]
|
| [18] |
Ke Y, Wang L, Li LQ, et al. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection[J]. World J Hepatol, 2014, 6(9): 652-9.
|
下载:
